Non-small cell lung cancer clinical trial NCT06012435

Learn about a clinical trial for people with previously treated non-small cell lung cancer (NSCLC).

The Be6A LUNG-01 clinical trial is researching the safety and effectiveness of a study medicine compared to the current standard therapy (docetaxel chemotherapy) in people who have been previously treated for their advanced NSCLC. The study medicine is designed to stick to cancer cells and kill them by delivering an anticancer treatment. The study medicine may also attach to non-cancer cells.

Who may participate

Deciding to take part in a clinical research study is an important and personal decision. Before you agree to take part, the study team will review all aspects of the clinical research study with you. You will be given a document called an Informed Consent Form that provides, in writing, details about the clinical trial including benefits and risks. You will have the opportunity to ask questions and are encouraged to speak with your own doctor to decide if taking part is right for you.

You may be able to take part in the clinical trial if you:

Have a confirmed diagnosis of locally advanced, unresectable Stage IIIB, IIIC, or metastatic Stage IV nonsquamous* NSCLC
Have received prior treatment for your condition
Were informed your cancer returned or got worse after your most recent treatment

This is not a complete list of the study’s eligibility criteria, and the study doctor will review all the criteria with you. Thank you for considering the Be6A LUNG-01 study.

*Nonsquamous refers to a type of lung cancer determined by a pathologist.

Condition

Non-small cell lung cancer (NSCLC)

Age

18+ years

Sex

Male or Female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

Get started — See if you may be eligible

Answer a 2-minute questionnaire.

A first step as you consider this study is to answer a 2-minute online questionnaire about your health and medical history. If your answers show the study might be a good fit for you, you may choose to have your contact information shared with a Pfizer Clinical Trial Contact Center Navigator.

Speak with a study representative.

If you’re interested, a Pfizer Clinical Trial Contact Center Navigator will call you and do a more detailed review of the study and your medical history to see if you may be able to participate and be referred to a study clinic that you select.

Confirm your eligibility.

Your answers to these questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you. Only the study staff can determine if you meet the study’s eligibility criteria and are able to enroll in the study.

What to expect

If you choose to participate and the study doctor determines the study is a good fit, you will be randomly assigned (like flipping a coin) to either the study medicine group (B6A) or the current standard therapy group (docetaxel). There is a 50/50 chance of getting assigned to either group. Your study doctor will know which group you are in. There is no placebo in this study.

It’s important to know that you may continue receiving the study medicine for up to 5 years. You or your study doctor may end your participation at any time if they feel the study isn’t helping you.

Additionally, you will get the following at no extra cost:

All study-related medical exams
Close monitoring of your cancer and overall health by doctors who specialize in lung cancer
Reimbursement (paid back) for some of your qualified travel and lodging costs for you or your caregiver, if applicable.

Length of study treatment

Up to 5 years

Number of study visits

Up to 2 visits per month after your first treatment cycle. Additional visits may be requested by your study doctor.

Why are we conducting the Be6A LUNG-01 study?

Each clinical trial has learning objectives. The main goals of this clinical trial are to understand:

whether life expectancy is extended
the percentage of patients who respond to the study medicine
whether there is an increase in the time that the cancer doesn’t spread
whether there are changes to/improvements in quality of life

This is not a complete list of the study’s goals. The study doctor can review the complete list with you.

Your safety while participating is our highest priority. If you have questions or concerns at any point throughout the clinical trial, a study team member is available. Your privacy will be maintained throughout this study. Your participation is voluntary, and you are free to withdraw from the study at any time.